Neurocrine Biosciences: Beyond Ingrezza, A Diversified Pipeline Fuels Its Next Growth Chapter

Related Articles

The Fed's Next Chapter: What a New Chair Means for Financial Markets

11 months ago

Is Kuros Biosciences' MagnetOs™ Poised for Explosive Growth

4 months ago

Macy's "Bold New Chapter" Delivers Surprising Growth, Challenging its Discounted Valuation

3 months ago

Silvercorp's China Headwinds Obscure a Diversified Growth Story with 28% Upside

4 months ago

Category

You may also like

Stock News•2 weeks ago

Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-'567 in Adults with Alzheimer's Disease

Neurocrine Biosciences initiated a Phase 2 study of NBI-'567, an oral M1/M4 muscarinic agonist, in adults with mild to moderate Alzheimer's disease as an adjunctive cognitive treatment. The trial star...

NBIX

Share

Stock News•2 months ago

Neurocrine's Crenessity Gains Ground in CAH: How Far Can Sales Go?

Neurocrine's Crenessity sales are rising rapidly in congenital adrenal hyperplasia (CAH), driven by low patient penetration that leaves significant room for growth.

CAH

Share

Stock News•2 months ago

Neurocrine Biosciences: 'House Full Of Options'

Neurocrine Biosciences is rated Buy on robust cash flows, strong launches, and a diversified pipeline. Ingrezza anchors profitability with exclusivity until 2038 and projected peak sales of $3.3B. Val...

NBIX

Share